Work

Comparative healthcare resource utilization and costs of empagliflozin and GLP ‐1 receptor agonists in type 2 diabetes

Year: 2025

Type: article

Study design: Observational Study

Source: Diabetes Obesity and Metabolism

DOI: 10.1111/dom.70195

Authors: Phyo Than Htoo, Helen Tesfaye, Sebastian Schneeweiss, Deborah J. Wexler, Robert J. Glynn, Elyse DiCesare, Ariel Freedman, Niklas Schmedt, Christina Shay, Julie M. Paik, Elisabetta Patorno

Institutions: Brigham and Women's Hospital, Harvard University, Massachusetts General Hospital, Boehringer Ingelheim (Germany)

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: American Diabetes Association, Boehringer Ingelheim, Food and Drug Administration, National Institute on Aging

Awards: G1040932999, Novel approaches to tailor cardioprotective glucose lowering medications in older adults with type 2 diabetes based on underlying cardiovascular risk, G5425462428, G5674455775

OpenAlex ID: W4415243731

FWCI:

Cites: 20

Cited by:

Related to: